Ema Flores-Díaz1, Karen A Sereday2, Silvaneide Ferreira1, Bradley Sirak2, João Simão Sobrinho1, Maria Luiza Baggio1, Lenice Galan3, Roberto C Silva4, Eduardo Lazcano-Ponce5, Anna R Giuliano2, Luisa L Villa1,6, Laura Sichero1. 1. Molecular Biology Laboratory, Center for Translational Research in Oncology, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil. 2. Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. 3. Ludwig Institute for Cancer Research, São Paulo Branch, São Paulo, Brazil. 4. Centro de Referência e Treinamento DST/Aids, São Paulo, Brazil. 5. Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, Cuernavaca, Mexico. 6. Department of Radiology and Oncology, Faculdade de Medicina, Universidade de São Paulo, Brazil.
Abstract
Background: Human papillomavirus type 6 (HPV-6) and HPV-11 are the etiological agents of approximately 90% of genital warts (GWs). The impact of HPV-6 genetic heterogeneity on persistence and progression to GWs remains undetermined. Methods: HPV Infection in Men (HIM) Study participants who had HPV-6 genital swabs and/or GWs preceded by a viable normal genital swab were analyzed. Variants characterization was performed by polymerase chain reaction sequencing and samples classified within lineages (A, B) and sublineages (B1, B2, B3, B4, B5). Country- and age-specific analyses were conducted for individual variants; odds ratios and 95% confidence intervals for the risk of GWs according to HPV-6 variants were calculated. Results: B3 variants were most prevalent. HPV-6 variants distribution differed between countries and case status. HPV-6 B1 variants prevalence was increased in GWs and genital swabs of cases compared to controls. There was difference in B1 and B3 variants detection in GW and the preceding genital swab. We observed significant association of HPV-6 B1 variants detection with GW development. Conclusions: HPV-6 B1 variants are more prevalent in genital swabs that precede GW development, and confer an increased risk for GW. Further research is warranted to understand the possible involvement of B1 variants in the progression to clinically relevant lesions.
Background: Human papillomavirus type 6 (HPV-6) and HPV-11 are the etiological agents of approximately 90% of genital warts (GWs). The impact of HPV-6 genetic heterogeneity on persistence and progression to GWs remains undetermined. Methods: HPV Infection in Men (HIM) Study participants who had HPV-6 genital swabs and/or GWs preceded by a viable normal genital swab were analyzed. Variants characterization was performed by polymerase chain reaction sequencing and samples classified within lineages (A, B) and sublineages (B1, B2, B3, B4, B5). Country- and age-specific analyses were conducted for individual variants; odds ratios and 95% confidence intervals for the risk of GWs according to HPV-6 variants were calculated. Results: B3 variants were most prevalent. HPV-6 variants distribution differed between countries and case status. HPV-6 B1 variants prevalence was increased in GWs and genital swabs of cases compared to controls. There was difference in B1 and B3 variants detection in GW and the preceding genital swab. We observed significant association of HPV-6 B1 variants detection with GW development. Conclusions: HPV-6 B1 variants are more prevalent in genital swabs that precede GW development, and confer an increased risk for GW. Further research is warranted to understand the possible involvement of B1 variants in the progression to clinically relevant lesions.
Authors: Laura Sichero; Silvaneide Ferreira; Helen Trottier; Eliane Duarte-Franco; Alex Ferenczy; Eduardo Luis Franco; Luisa Lina Villa Journal: Int J Cancer Date: 2007-04-15 Impact factor: 7.396
Authors: Lisa Mirabello; Meredith Yeager; Michael Cullen; Joseph F Boland; Zigui Chen; Nicolas Wentzensen; Xijun Zhang; Kai Yu; Qi Yang; Jason Mitchell; David Roberson; Sara Bass; Yanzi Xiao; Laurie Burdett; Tina Raine-Bennett; Thomas Lorey; Philip E Castle; Robert D Burk; Mark Schiffman Journal: J Natl Cancer Inst Date: 2016-04-29 Impact factor: 13.506
Authors: Anna R Giuliano; Eduardo Lazcano-Ponce; Luisa L Villa; Roberto Flores; Jorge Salmeron; Ji-Hyun Lee; Mary R Papenfuss; Martha Abrahamsen; Emily Jolles; Carrie M Nielson; Maria Luisa Baggio; Roberto Silva; Manuel Quiterio Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-08 Impact factor: 4.254
Authors: L Ho; S Y Chan; R D Burk; B C Das; K Fujinaga; J P Icenogle; T Kahn; N Kiviat; W Lancaster; P Mavromara-Nazos Journal: J Virol Date: 1993-11 Impact factor: 5.103
Authors: Laura Sichero; Mariam El-Zein; Silvaneide Ferreira; Eduardo L Franco; Luisa L Villa Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-03-13 Impact factor: 4.254
Authors: P I Marques; J C Gonçalves; C Monteiro; B Cavadas; L Nagirnaja; N Barros; A Barros; F Carvalho; A M Lopes; S Seixas Journal: Andrology Date: 2019-04-19 Impact factor: 3.842
Authors: Taek Sang Lee; Smita Kothari-Talwar; Puneet K Singhal; Karen Yee; Amit Kulkarni; Nuria Lara; Montserrat Roset; Anna R Giuliano; Suzanne M Garland; Woong Ju Journal: BMJ Open Date: 2019-03-20 Impact factor: 2.692